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ABSTRACT 
Objective: The current work mainly focuses on solubility enhancement of dolutegravir which is a BCS (Biopharmaceutical Classification System) 
class-II drug using various excipients. 
Methods: Solid dispersions of dolutegravir were prepared by solvent evaporation and fusion methods using carriers like poloxamer-188 and plasdone 
K-29/32 in different ratios (1:0.5 to 1:3.0). The amount of dolutegravir used was kept constant and the polymer concentrations were increased. Various 
physical parameters like angle of repose, carr’s index, Hausner’s ratio were calculated for the prepared solid dispersions. They were also evaluated for 
particle size and drug content uniformity along with in vitro drug release. Characterization studies like Fourier Transform Infra-Red spectroscopy 
(FTIR), Differential Scanning Calorimetry (DSC), Scanning Electron Microscopy (SEM) and X-Ray Diffraction (XRD) were also done. 
Results: Dolutegravir solid dispersions showed good to excellent flow properties. From in vitro dissolution studies, it was observed that the solid 
dispersion formulation DF3 containing dolutegravir and poloxamer-188 in 1:1.5 ratios prepared by fusion method showed better dissolution rate 
when compared with other formulations. The dissolution parameters were also evaluated. DF3 showed a higher drug release of 86.33% in 60 min. 
FTIR and DSC studies revealed that there were no major interactions between drug and excipients. XRD studies revealed the nature of formulations. 
Conclusion: The solid dispersions prepared using poloxamer-188 by fusion method has enhanced the solubility of dolutegravir. 
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INTRODUCTION 
Solubility is a major physicochemical factor which affects the drug 
absorption and its therapeutic efficiency. Solubility enhancement is 
the main area that researchers were focusing in recent days. Several 
methods like usage of polymers, superdisintegrants, preparation of 
formulations like solid dispersions and fast dissolving tablets has 
been employed in solubility enhancement. Of all these, preparation 
of solid dispersions is the best choice of researchers as they are easy 
to prepare, economic and time saving [1]. The term solid dispersion 
refers to a group of solid products consisting of at least two different 
components, a hydrophilic matrix and a hydrophobic drug [2]. They 
can be prepared by simple physical mixing, solvent evaporation and 
fusion techniques. Miscibility of polymers with the drug plays a key 
role in solubility enhancement of poorly water soluble drugs [3].  
The present study was aimed to formulate dolutegravir solid 
dispersions using various polymers to improve the solubility and 
dissolution rate. Dolutegravir, an antiretroviral agent mainly acts by 
inhibiting the enzyme HIV integrase which is needed for viral 
replication process [4]. According to the Biopharmaceutical 
Classification Scheme, dolutegravir is considered as class II drug, i.e., 
water insoluble, lipophilic and highly permeable compound. 
Therefore, it is possible to improve its bioavailability by increasing 
apparent solubility in water through solid dispersion technology [5, 
6]. The bioavailability of dolutegravir is approximately 34%. It is 
highly bound to plasma proteins. It has an approximate elimination 
half-life of 14h. Based on pharmacokinetic and pharmacodynamic 
parameters, Dolutegravir is selected as drug of choice for present 
study. The current study focused on the solubility enhancement of 
dolutegravir using solid dispersion technology. 
MATERIALS AND METHODS 
Procurement of materials 
Dolutegravir was a gift sample from Dr. Reddy’s Lab (Hyderabad, 
India). Poloxamer 188 and plasdone K-29/32 were gift samples from 
Pellets Pharma Ltd (Hyderabad, India). 
Preparation of dolutegravir solid dispersions by solvent 
evaporation method 
Specified quantities of dolutegravir and poloxamer-188 were taken 
in a china dish and to that few ml of methanol was added and 
slightly heated until both drug and polymer dissolves. Then the 
mixture was subsequently allowed to evaporate. The obtained 
mixture was dried, passed through the sieve no.80, packed in a wide 
mouthed amber colored glass container and was hermetically sealed 
and stored [7]. Similarly, the solid dispersions were prepared using 
plasdone K-29/32 as polymer. The results were given in table 1. 
Preparation of dolutegravir solid dispersions by fusion method 
Solid dispersions of Dolutegravir were prepared using poloxamer-
188 and plasdone K-29/32 in different ratios by fusion method. 
Poloxamer-188 was placed in china dish and heated at 40 °C until it 
gets melted and then dolutegravir was added to it. After vigorous 
stirring in normal temperature, the mixture gets solidified. The solid 
mass was crushed, pulverized and sieved [8]. Similarly, the solid 
dispersions were prepared using plasdone K-29/32 as carrier. The 
granules obtained were stored in desiccator for further studies. The 
results were given in table 2. 
Evaluation of physical parameters of dolutegravir solid 
dispersions 
The prepared solid dispersions were evaluated for various physical 
parameters such as angle of repose, Carr’s index, Hausner's ratio and 
particle size [9, 10]. The results were indicated in table 3. 
Angle of repose 
The powder flow properties were determined to know the good or bad 
material flow. The powder was taken into a funnel and poured through 
it. Below this, a graph sheet was placed to form a heap like structure for 
which, the radius and height of the heap was measured. Based on these, 
the angle of repose was calculated by using the formula;  θ = tan-1 (h/r) 
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Carr’s index 
A simple test was used to evaluate the flow ability of a powder by 
comparing the poured density and the tapped density of a powder 
and the rate at which it is packed down. Carr′s Index = Tapped density − Poured densityTapped density  x 100 
Hausner’s ratio 
It is an indication of flow properties of the powder. Hausner’s ratio 
can be calculated by using the formula;  Hausner′s Ratio = Tap densityBulk density 
Particle size 
A set of sieves were taken, properly cleaned and are stacked in 
descending order of mesh size (increase in the sieve number). The 
solid dispersion was taken in the sieve number 18. The sieves are 
closed with lid and sieving was done for 5 min. The material 
retained on individual sieves were collected and weighed. 
Drug content uniformity 
Solid dispersions of dolutegravir equivalent to 50 mg was weighed 
and transferred into a 100 ml volumetric flask. To this, small 
quantity of methanol was added to dissolve. It was shaken 
occasionally for about 15 min and the volume was made up to 100 
ml by methanol. The solution was filtered using Whattmann filter 
paper. The filtrate was subsequently diluted with 6.8pH phosphate 
buffer and the absorbance was measured at 258 nm using 6.8pH 
phosphate buffer as blank. 
In vitro dissolution studies 
Dissolution studies for all solid dispersions were performed in a 
calibrated 8 station dissolution test apparatus (LABINDIA DS8000) 
equipped with paddles (USP apparatus II method) employing 900 ml 
of 6.8pH phosphate buffer as a dissolution medium. The paddles were 
operated at 50 rpm and temperature was maintained at 37±1 °C 
throughout the experiment [11]. The samples were withdrawn at 5, 
10, 15, 20, 30, 45, 60 min and replaced with equal volume of same 
dissolution medium to maintain the sink conditions throughout the 
experiment. Samples withdrawn were suitably diluted with same 
dissolution medium and the amount of the drug dissolved was 
estimated by Lab India double beam U. V spectrophotometer (UV 
3000+) at 258 nm. The dissolution profiles were indicated in fig. 1 
and 2. Various dissolution parameters were calculated for the 
dispersions and were given in table 4. 
Statistical analysis 
The results obtained were statistically evaluated. As the procedures 
performed and the results obtained were in triplicates, the mean 
along with their standard deviations (SD) were calculated for drug 
content and drug dissolution profiles. 
Characterization studies 
Based on the dissolution studies, the optimized formulations were 
selected, and Fourier transfer infrared (FTIR) and differential 
scanning calorimetry (DSC) studies were performed to observe the 
drug-polymer interactions. X-Ray Diffraction (XRD) studies were 
performed to detect the nature of formulations. Scanning electron 
microscopy (SEM) analysis was performed on dolutegravir, 
poloxamer-188 and optimized solid dispersion to know surface 
characteristics. The results were shown in fig. 3, 4, 5 and 6. 
RESULTS AND DISCUSSION 
Preparation of dolutegravir solid dispersions by solvent 
evaporation method 
Solid dispersions of Dolutegravir were prepared using poloxamer-
188 and plasdone K-29/32 in different ratios by solvent evaporation 
method. The composition of dolutegravir solid dispersions prepared 
by solvent evaporation method is given the table 1. 
Preparation of dolutegravir solid dispersions by fusion method 
Solid dispersions of Dolutegravir were prepared using poloxamer-
188 and plasdone K-29/32 in different ratios by fusion method. The 
composition of dolutegravir solid dispersions prepared by fusion 
method is given the table 2. 
 
Table 1: Composition of dolutegravir solid dispersions prepared by solvent evaporation method 




Drug: polymer ratio 
(Dolutegravir*: plasdone K-29/32) 
DS1 1:0.5 DS6 1:0.5 
DS2 1:1.0 DS7 1:1.0 
DS3 1:1.5 DS8 1:1.5 
DS4 1:2.0 DS9 1:2.0 
DS5 1:3.0 DS10 1:3.0 
*One part is equal to 50 mg 
 
Table 2: Composition of dolutegravir solid dispersions prepared by fusion method 




Drug: polymer ratio 
(Dolutegravir*: plasdone K-29/32) 
DF1 1:0.5 DF6 1:0.5 
DF2 1:1.0 DF7 1:1.0 
DF3 1:1.5 DF8 1:1.5 
DF4 1:2.0 DF9 1:2.0 
DF5 1:3.0 DF10 1:3.0 
*One part is equal to 50 mg 
 
Evaluation of physical parameters of dolutegravir solid 
dispersions 
Various physical parameters of dolutegravir solid dispersions were 
evaluated. The obtained results were indicated in table 3. 
Formulations prepared using dolutegravir and poloxamer-188 by 
fusion method showed good flow properties compared to others. 
In vitro dissolution studies of dolutegravir solid dispersions 
Dolutegravir pure drug showed only 13.33% of drug release even 
after 60 min. This indicates its poor aqueous solubility as it is a BCS 
class II drug. Formulation DF3, prepared in 1:1.5 ratios of 
dolutegravir and poloxamer-188 showed maximum drug release of 
86.33% in 60 min. It proves that solid dispersion technique 
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enhances drug release of poorly water soluble drugs as suggested by 
earlier studies [12, 13]. The fusion technique used for formulation of 
solid dispersions was also proved to be most advantageous as 
suggested earlier [14-16]. Usage of carriers increases the dissolution 
efficiency [17, 18]. Poloxamer-188 is a non-ionic surfactant which 
basically consists of both hydrophilic and lipophilic moieties. Hence 
the increase in drug release followed by decrease in drug release 
may be due to presence of high proportion of lipophilic moieties at 
higher concentration of polymer used in the dispersions [19, 20]. 
Apart from these, other polymers like PVP and PEG were also used 
in past studies to enhance solubility of BCS class-II drugs [21]. Thus 
solid dispersions DF3 containing drug to polymer ratio of 1:1.5 was 
found to be optimal concentration of the carrier for the preparation 
of solid dispersions. The dissolution profiles were indicated in fig. 1 
and 2. The dissolution parameters were given in table 4. The first 
order plots revealed the linearity in drug release. 
 
Table 3: Physical parameters of dolutegravir solid dispersions 
Solid dispersion Angle of repose (°) Carr’s index (%) Hausner's ratio Average particle size 
(μm) 
Drug content (mg) 
(mean±SD)* 
DD 32 19 1.22 35 49.45±0.66 
DS1 28 15 1.17 179 48.71±0.59 
DS2 26 14 1.15 171 49.63±0.17 
DS3 24 12 1.13 165 50.20±0.77 
DS4 25 13 1.15 174 48.92±0.81 
DS5 25 14 1.15 176 48.45±0.59 
DS6 29 15 1.18 181 49.16±0.17 
DS7 27 13 1.16 175 49.08±0.54 
DS8 26 13 1.14 169 48.66±0.41 
DS9 26 12 1.16 173 49.25±0.77 
DS10 28 14 1.16 176 48.82±0.81 
DF1 25 14 1.16 171 48.35±0.54 
DF2 23 13 1.14 164 49.62±0.41 
DF3 21 12 1.12 158 50.08±0.77 
DF4 23 13 1.14 165 48.73±0.81 
DF5 25 14 1.15 169 48.12±0.59 
DF6 27 15 1.18 177 49.08±0.17 
DF7 25 14 1.16 172 50.23±0.54 
DF8 22 13 1.15 166 49.24±0.41 
DF9 24 12 1.17 171 48.07±0.77 
DF10 25 13 1.17 175 48.65±0.81 
 *DD indicates Dolutegravir pure drug; n=3, SD: standard deviation 
 
 
Fig. 1: Drug release profiles of dolutegravir solid dispersions prepared by solvent evaporation method (mean±SD; n=3) 
 
 
Fig. 2: Drug release profiles of dolutegravir solid dispersions prepared by fusion method (mean±SD; n=3) 
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Table 4: In vitro dissolution parameters of dolutegravir solid dispersions 
Formulation % Drug released at 60 
min 
T50 (min) DE20% First order rate constant Hixson crowell cube root plot 
K (min-1) R2 K (min-1/3) R2 
DD 13.34 >60 6.50 0.0019 0.711 0.0016 0.787 
DS1 47.11 >60 26.25 0.0092 0.901 0.0071 0.915 
DS2 58.88 20.44 32.50 0.0128 0.924 0.0095 0.960 
DS3 73.21 10.78 42.50 0.0199 0.965 0.0138 0.978 
DS4 61.19 19.87 33.75 0.0133 0.964 0.0096 0.931 
DS5 49.18 >60 28.75 0.0092 0.933 0.0066 0.905 
DS6 43.16 >60 23.12 0.0085 0.910 0.0063 0.922 
DS7 50.63 59.25 28.12 0.0100 0.928 0.0075 0.935 
DS8 58.58 19.70 34.37 0.0123 0.975 0.0087 0.944 
DS9 52.64 29.55 28.12 0.0108 0.951 0.0082 0.901 
DS10 46.01 >60 23.75 0.0087 0.904 0.0068 0.937 
DF1 64.55 15.84 36.87  0.0151 0.900 0.0108 0.969 
DF2 75.22 10.37 43.75 0.0202 0.922 0.0136 0.948 
DF3 86.33 05.18 53.12 0.3065 0.988 0.0190 0.983 
DF4 77.08 09.76 46.25 0.0219 0.933 0.0144 0.924 
DF5 66.32 14.64 40.00 0.0157 0.905 0.0107 0.953 
DF6 56.99 20.32 32.5 0.0120 0.962 0.0087 0.911 
DF7 64.22 15.43 40.00 0.0147 0.941 0.0100 0.960 
DF8 77.53 09.89 46.25 0.0220 0.920 0.0145 0.948 
DF9 70.05 10.57 42.50 0.0172 0.939 0.0218 0.933 
DF10 60.08 16.48 37.50 0.0133 0.919 0.0096 0.917 
 
Characterization studies 
Based on the dissolution studies performed on all the formulations, 
the optimized formulations were selected and following studies 
were done. 
Fourier-transform infra-red (FT-IR) spectroscopic analysis 
The FTIR spectral investigations were conducted on dolutegravir 
pure drug, poloxamer-188 and optimized dolutegravir solid 
dispersion. The pure drug dolutegravir exhibited sharp peak at 
2234.96 cm-1, 1393.32 cm-1, 856.65 cm-1 and 885.53 cm-1 indicating 
the presence of C-N stretching, C≡C stretching, C-O-C stretching, C-H 
bending and Ar-H bending. For Poloxamer-188, sharp peaks at 
2237.60 cm-1, 2165.00 cm-1and 842.24 cm-1 indicated C-N stretching, C≡C stretching and C-H bending. For DF3 solid dispersion, sharp 
peaks at 2237.12 cm-1, 2165.40 cm-1, 1391.18 cm-1and 842.24 cm-1 
indicated C-N stretching, C≡C stretching, C-O-C stretching and Ar-H 
bending. The remaining peaks were unaltered indicating that there 
were no drug and excipients interaction. The detailed spectral 
elucidations were shown in fig. 3. 
 
 
(A)     (B)     (C) 
Fig. 3: FTIR Spectra: (A) Dolutegravir pure drug (B) Poloxamer-188 (C) DF3 solid dispersion, DF3–solid dispersion of dolutegravir and 
poloxamer-188 in 1:1.5 ratio 
 

























































































(A)     (B)     (C) 
Fig. 4: DSC Thermograms: (A) Dolutegravir pure drug (B) Poloxamer-188, (C) DF3 solid dispersion, DF3–solid dispersion of dolutegravir 
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Differential Scanning Calorimetry (DSC): 
A differential scanning calorimeter (DSC 200F3, Shimadzu) was used 
to obtain the DSC curves of dolutegravir pure drug, poloxamer-188 
and solid dispersion DF3 representing the rates of heat uptake. The 
DSC results revealed that sharp peaks for dolutegravir were 
observed at 371.780C, 3800C and 3890C. A sharp endothermic peak 
for poloxamer-188 was observed at 59.50C. Sharp and broad peaks 
for DF3 were observed at 57.470C, 345.800C and 373.680C. These 
studies revealed that there were no drug and excipient interactions 
which were confirmed by obtaining similar thermographic peaks at 
respective temperatures. The detailed thermographs were shown in 
fig. 4. 
Powder X-ray diffractometry (PXRD) 
Powder X-ray diffraction (PXRD) patterns were traced employing X-
ray diffractometer Shimadzu and DSC-60, Germany for all the samples 
using Nickel filter, CuK (α) radiation, a current of 20 mA and receiving 
slit of 0.2 inches. PXRD studies of dolutegravir showed several sharp 
peaks from 10 to 40 θ degrees. The PXRD studies for poloxamer-188 
showed only two sharp peaks at 20 to 30 θ degree. The solid 
dispersion prepared by dolutegravir and polaxmer-188 revealed that 
sharp peaks corresponding to the polymer were observed at 20 to 30 θ degree. This indicated that the crystalinity of pure drug was greatly 
reduced by solid dispersion formulation having poloxamer 188. The 
powder x-ray diffraction patterns were shown in fig. 5. 
 
 
(A)     (B)     (C) 
Fig. 5: XRD Diffractograms: (A) Dolutegravir pure drug (B) Poloxamer-188, (C) DF3 solid dispersion, DF3–solid dispersion of 
dolutegravir+poloxamer-188 in 1:1.5 ratio 
 
Scanning electron microscopy 
SEM images were taken for Dolutegravir pure drug, poloxamer-
188 and solid dispersion DF3. SEM photographs of 
dolutegravir exhibited high crystalinity of drug with several 
planes of surface. Poloxamer-188 exhibited spherical shaped 
granular form of beads. Solid dispersion DF3 showed that the 
drug was absorbed on to the spherical beads and there by the 
crystalinity of drug is greatly reduced. The SEM images were 
clearly shown in the fig. 6. 
 
 
(A)     (B)     (C) 
Fig. 6: SEM Images: (A) Dolutegravir pure drug (B) Poloxamer-188 (C) DF3 solid dispersion, DF3–solid dispersion of dolutegravir and 
poloxamer-188 in 1:1.5 ratio 
 
CONCLUSION 
Dolutegravir solid dispersions were prepared using various 
concentrations of poloxamer-188 and plasdone K-29/32 using 
solvent evaporation and fusion methods and were subjected to in 
vitro dissolution studies. From these studies, it was observed that 
the proportion of carrier has influenced the dissolution parameters 
of various formulations. Poloxamer-188 has greatly modified the 
solubility of dolutegravir when solid dispersions were prepared by 
fusion method. The optimized solid dispersions when subjected to 
FTIR and DSC analysis, showed no drug-excipient interactions. 
Similarly, XRD studies were conducted to know the crystalline and 
amorphous nature of the samples. 
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